ACT Brief: Site Relationships and Payment Reliability, AI Adoption Without Governance Risk, and China's Biotech Innovation Rise

This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.

• In part four of his interview, Patrick Mizer, chief technology officer at Ledger Run, explains how unpredictable payments erode site relationships over time. Operational excellence in payments is becoming increasingly important to landing and retaining the best investigative sites, shifting payment infrastructure from a back-office commodity into a competitive differentiator in site competition.
• In a new contributed article, Philip Raeth examined how AI is reshaping clinical research faster than any technology before it, but adoption without GxP-grade governance, validation, and human oversight is not strategy, it is risk. The regulatory expectation that human decision-makers maintain responsibility for outcomes remains regardless of how quickly new models arrive or how compelling their performance appears.
• In a new Q&A from Pharmaceutical Executive, Dr. Ying Huang, CEO of K2 Therapeutics, discussed why China's biotech ecosystem is driving innovation at scale, with licensing commitments reaching $51.9 billion in 2024, a 90% jump from 2023. Public investment in basic science across Asia is translating into industrial R&D productivity, creating an entrepreneurial ecosystem of approximately three to four thousand biotech companies that Western pharma is now accessing through global asset acquisition.

That's all for today's ACT Brief. Join us next week for more updates shaping clinical operations and drug development. Thanks for listening.